Competition for additional information. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong ...
Q2 FY2026 — expected 2026-08-23
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001193125-26-065197 | EDGAR | 88K words |
| 2025-02-25 | 2024-12-31 | 0000950170-25-026068 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-021074 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0000950170-23-006841 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0000950170-22-002727 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001564590-21-010715 | EDGAR | — |
| 2020-03-05 | 2019-12-31 | 0001564590-20-008951 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-29 | 2025-09-30 | 0001193125-25-254633 | EDGAR | 56K words |
| 2025-07-29 | 2025-06-30 | 0000950170-25-099407 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0000950170-25-061442 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-125931 | EDGAR | — |
| 2024-07-31 | 2024-06-30 | 0000950170-24-088238 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058193 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-059755 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037579 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021960 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-022913 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016644 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000950170-22-008235 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-24 | 0001193125-26-065190 | EDGAR | 2K words |
| 2026-01-12 | 0001193125-26-009845 | EDGAR | — |
| 2025-12-11 | 0001193125-25-314728 | EDGAR | — |
| 2025-12-08 | 0001193125-25-310509 | EDGAR | — |
| 2025-10-29 | 0001193125-25-254619 | EDGAR | — |
| 2025-08-28 | 0001193125-25-190746 | EDGAR | — |
| 2025-07-29 | 0000950170-25-099404 | EDGAR | — |
| 2025-06-27 | 0001193125-25-151276 | EDGAR | — |
| 2025-05-01 | 0000950170-25-061439 | EDGAR | — |
| 2025-03-04 | 0000950170-25-032355 | EDGAR | — |
130 total filings indexed. 101 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001680581 |
| Ticker | FULC |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.fulcrumtx.com |
| Listed | 2019-07-18 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report